Clinical Trials Logo

Schizophrenia Schizoaffective clinical trials

View clinical trials related to Schizophrenia Schizoaffective.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06275451 Not yet recruiting - Schizophrenia Clinical Trials

Qualitative Study of Emotional Regulation in Schizophrenia

QUALI-RES
Start date: February 2024
Phase:
Study type: Observational

The main aim of this study is to investigate emotional regulation in individuals with schizophrenia using a qualitative methodology (semi-structured interview) and, therefore, from the person's point of view. Given the qualitative nature of the methodology used in this study, the investigators have no specific hypothesis. The investigators have a general hypothesis suggesting that the patients' discourse will enable us to highlight the emotional regulation difficulties described in the literature.

NCT ID: NCT03461432 Not yet recruiting - Clinical trials for Schizophrenia Schizoaffective

Personalised Cognitive Remediation Therapy (pCRT)

pCRT
Start date: October 31, 2018
Phase: N/A
Study type: Interventional

Cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia. There is evidence that Cognitive Remediation Therapy, a form of psychological therapy, is effective in improving cognition and functioning but there is still a limited understanding of what influence people's different response to this therapy. A tailored treatment is likely to be more effective because it will adapt to service users' unique characteristics. The investigators are planning a study exploring at the feasibility and acceptability of novel form of Cognitive Remediation Therapy which is personalised (pCRT) to the person individual characteristics. The personalised therapy will consist of task practice using computerized Cognitive Remediation software (i.e. called CIRCuiTS). The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.